Featured Research

from universities, journals, and other organizations

Use Of Non-Steroidal Anti-Inflammatory Drugs Suspended In Large Alzheimer's Disease Prevention Trial

Date:
December 23, 2004
Source:
National Institutes Of Health
Summary:
The National Institutes of Health (NIH) announced that research investigators suspended, until further notice, the use of two drugs, naproxen (220 mg twice a day) and celecoxib (200 mg twice a day), in a large, three-arm, national Alzheimer’s disease prevention trial sponsored by the National Institute on Aging (NIA), a part of the NIH.

December 20, 2004 -- The National Institutes of Health (NIH) announced today that research investigators suspended, until further notice, the use of two drugs, naproxen (220 mg twice a day) and celecoxib (200 mg twice a day), in a large, three-arm, national Alzheimer’s disease prevention trial sponsored by the National Institute on Aging (NIA), a part of the NIH. The trial, called the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (or ADAPT) was designed to assess the potential benefit of long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) — naproxen (Aleve™) and the COX-2 inhibitor celecoxib (Celebrex™ ) in decreasing the risk of developing Alzheimer’s Disease in people 70 years of age or older who were considered to be at increased risk because of family history, but did not have symptoms of the disease.

Approximately 2400 volunteer participants were randomly assigned to receive naproxen, celecoxib, or placebo for periods of time up to three years. Although no significant increase in risk for celecoxib was found in this trial, the use of these drugs in the study was suspended in part because of findings reported last week from a National Cancer Institute (NCI) trial to test the effectiveness of celecoxib in preventing colon cancer. In addition, however, data from the ADAPT trial indicated an apparent increase in cardiovascular and cerebrovascular events among the participants taking naproxen when compared with those on placebo.

“This step is being taken as a precautionary measure to ensure the safety of the study’s participants,” said NIH Director, Elias A. Zerhouni, M.D. “The investigators made their decision based on the risk/benefit analysis specific to this trial,” added Dr. Zerhouni.

The ADAPT trial began in 2001 and was conducted at six sites across the U.S. — Tampa, FL; Rochester, NY; Baltimore, MD; Sun City, AZ; Seattle, WA; and, Boston, MA. The principal investigator for the study is John Breitner, M.D., of the Veterans Affairs Medical Center Puget Sound and the University of Washington.

Investigators and NIH scientists will continue to review this and other NSAIDs studies sponsored by NIH in the light of these findings. It should be pointed that the cancer prevention trials and the ADAPT study are among the first long-term, clinical trials to test these classes of drugs. These studies are examining these compounds for uses very different from the uses for which these medications are currently approved. NIH and FDA will work together to provide the public with information they need to make informed health decisions.

Information for the public and health professionals will be posted at http://www.nih.gov as soon as additional data become available.

###

The NIH comprises the Office of the Director and 27 Institutes and Centers. The Office of the Director is the central office at NIH, and is responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components. The NIH, the Nation's medical research agency, is a component of the U.S. Department of Health and Human Services.

The NIA is one of 27 Institutes and Centers at the NIH. It leads the Federal Government effort conducting and supporting research on the biomedical and social and behavioral aspects of aging and the problems of older people. For more information on aging-related research and the NIA, please visit the NIA website at http://www.nia.nih.gov. The public may also call for publications describing these efforts and offering health information for older people and their families at 1-800-222-2225, the toll free number for the National Institute on Aging Information Center.


Story Source:

The above story is based on materials provided by National Institutes Of Health. Note: Materials may be edited for content and length.


Cite This Page:

National Institutes Of Health. "Use Of Non-Steroidal Anti-Inflammatory Drugs Suspended In Large Alzheimer's Disease Prevention Trial." ScienceDaily. ScienceDaily, 23 December 2004. <www.sciencedaily.com/releases/2004/12/041222231157.htm>.
National Institutes Of Health. (2004, December 23). Use Of Non-Steroidal Anti-Inflammatory Drugs Suspended In Large Alzheimer's Disease Prevention Trial. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2004/12/041222231157.htm
National Institutes Of Health. "Use Of Non-Steroidal Anti-Inflammatory Drugs Suspended In Large Alzheimer's Disease Prevention Trial." ScienceDaily. www.sciencedaily.com/releases/2004/12/041222231157.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins